Annex B H, Denning S M, Channon K M, Sketch M H, Stack R S, Morrissey J H, Peters K G
Division of Cardiology, Duke University Medical Center, Durham, NC 27705.
Circulation. 1995 Feb 1;91(3):619-22. doi: 10.1161/01.cir.91.3.619.
Tissue factor (TF) is a cell membrane-associated protein that catalyzes the rate-limiting step of the extrinsic coagulation pathway, which is the major source of thrombin production in vivo. To explore the potential role that TF may play in ischemic coronary syndromes, directional coronary atherectomy specimens were tested for the presence of TF protein using immunohistochemical techniques.
Frozen sections from atherectomy specimens in 61 patients were examined for TF expression using an IgG murine monoclonal antibody against human TF. Patients were classified according to their admission diagnosis as having either an unstable or a stable coronary syndrome. An unstable coronary syndrome was defined as either angina pectoris occurring at rest or post-myocardial infarction (< 1 week) angina. Stable coronary syndromes included patients with stable, progressive, and new-onset (< 6 weeks) angina without rest pain. TF was detected in 15 (43%) of 35 patients with unstable coronary syndromes versus only 3 (12%) of 26 patients with stable coronary syndromes (odds ratio, 5.7; 95% confidence interval, 1.3 to 24.3; P = .018). Within the subgroup of patients with unstable coronary syndromes, TF was detected in 14 (60%) of 25 patients with de novo lesions versus only 1 (10%) of 10 patients with a restenosis lesion (P < .02). An additional 8 patients with stable coronary syndromes due to a restenosis lesion were also negative for TF. Therefore, the overall incidence of TF expression was only 6% (1 of 18) in restenosis lesions compared with 33% (14 of 43) in de novo lesions (P < .03).
This study provides the first description of TF protein expression in human coronary artery lesions in vivo. Tissue factor was readily detected in de novo lesions in patients with unstable coronary syndromes, suggesting a role for TF in the pathogenesis of this disease process. Conversely, TF was rarely detected in patients with restenosis lesions even if the resulting clinical presentation was an unstable coronary syndrome. These results may have implications for the management of patients with unstable angina from de novo lesions and patients with ischemic symptoms from a restenosis lesion.
组织因子(TF)是一种与细胞膜相关的蛋白质,它催化外源性凝血途径的限速步骤,而外源性凝血途径是体内凝血酶产生的主要来源。为了探究TF在缺血性冠状动脉综合征中可能发挥的潜在作用,我们使用免疫组织化学技术对定向冠状动脉斑块旋切术标本进行TF蛋白检测。
我们使用抗人TF的IgG鼠单克隆抗体,对61例患者的斑块旋切术标本冰冻切片进行TF表达检测。患者根据入院诊断分为不稳定型或稳定型冠状动脉综合征。不稳定型冠状动脉综合征定义为静息性心绞痛或心肌梗死后(<1周)心绞痛。稳定型冠状动脉综合征包括稳定型、进行性和新发(<6周)无静息痛心绞痛患者。35例不稳定型冠状动脉综合征患者中有15例(43%)检测到TF,而26例稳定型冠状动脉综合征患者中仅3例(12%)检测到TF(优势比,5.7;95%置信区间,1.3至24.3;P = 0.018)。在不稳定型冠状动脉综合征患者亚组中,25例新发病变患者中有14例(60%)检测到TF,而10例再狭窄病变患者中仅1例(10%)检测到TF(P < 0.02)。另外8例因再狭窄病变导致稳定型冠状动脉综合征的患者TF检测也为阴性。因此,再狭窄病变中TF表达的总体发生率仅为6%(18例中的1例),而新发病变中为33%(43例中的14例)(P < 0.03)。
本研究首次描述了体内人冠状动脉病变中TF蛋白的表达情况。在不稳定型冠状动脉综合征患者的新发病变中很容易检测到组织因子,提示TF在该疾病过程的发病机制中发挥作用。相反,即使最终临床表现为不稳定型冠状动脉综合征,再狭窄病变患者中也很少检测到TF。这些结果可能对新发病变的不稳定型心绞痛患者和再狭窄病变的缺血症状患者的管理具有重要意义。